Heart failure with preserved ejection fraction and obesity — compounds assessed

§4Compounds assessed

Compounds the Institute assesses in this indication, with the class of each and its overall certainty. A compound appears here whether or not the evidence supports its use, because recording that a compound has been studied and found wanting is as much part of the assessment as recording that one has not.

• Semaglutide in hfpef

  GLP-1 receptor agonist (acylated, long-acting)2 contributing trialsfull monograph

  KCCQ clinical summary score improvement of 7.8 points versus placebo at 52 weeks — Downgraded one level for risk of bias: weight change is visible to participants and the primary endpoint is patient-reported.

  Moderate
• Tirzepatide in hfpef

  Dual GIP and GLP-1 receptor agonist (acylated)1 contributing trialfull monograph

  Composite of cardiovascular death or worsening heart failure hazard ratio 0.62 — Downgraded for imprecision — the composite was driven by heart-failure events with wide confidence limits.

  Moderate
• SS-31 (elamipretide) in hfpef

  Mitochondria-targeted cardiolipin-binding tetrapeptide1 contributing trialfull monograph

  A phase 2 trial in heart failure with preserved ejection fraction did not demonstrate benefit on the primary endpoint — Small sample.

  Low

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183 · PMID 33567185

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.